Business Context and Reporting Period
This Form 8-K is a current report filed by Enochian Biosciences, Inc. (not Lunai Bioworks Inc.) on November 14, 2019. The filing discloses a corporate governance change involving the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Board Expansion: The Board of Directors increased its size from 7 to 8 members.
- New Appointment: William A. Haselstine, PhD, was appointed as a new director. Dr. Haselstine is noted for his work in cancer, HIV/AIDS, and genomics, having founded over a dozen biotechnology companies.
Compensation and Management Commentary
Dr. Haselstine's annual compensation package for his service as a director includes:
- Cash Compensation: $60,000
- Stock Options: $75,000
Management confirmed there are no other arrangements or understandings regarding this appointment and no actual or proposed transactions requiring disclosure under Item 404(a) of Regulation S-K. No family relationships exist between Dr. Haselstine and other directors or executive officers.
Investor Verification Checklist
- Verify the correct registrant name is Enochian Biosciences, Inc. (Ticker: ENOB), not Lunai Bioworks Inc.
- Confirm the total annual cost of the new director appointment ($135,000) against the company's current cash reserves.
- Review the company's recent 10-K or 10-Q filings for financial context, as this 8-K contains no financial statements.
- Assess the strategic value of Dr. Haselstine's specific expertise in genomics and HIV/AIDS relative to the company's current pipeline.